Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_4
1
25%
Ph phase_1
1
25%
Ph phase_3
1
25%
Ph not_applicable
1
25%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
N/A1 (25.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors

NCT02840149
completedphase_1

Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia

NCT03736564
completednot_applicable

Dotatate to Locate Coronary Plaques at High-risk of Myocardial Infarction

NCT05536960
completedphase_4

d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis

NCT03549598

Clinical Trials (4)

Showing 4 of 4 trials
NCT02840149Phase 3

SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors

Completed
NCT03736564Phase 1

Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia

Completed
NCT05536960Not Applicable

Dotatate to Locate Coronary Plaques at High-risk of Myocardial Infarction

Completed
NCT03549598Phase 4

d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4